CN101348789B - 通过同源重组在人细胞中生产人突变蛋白 - Google Patents
通过同源重组在人细胞中生产人突变蛋白 Download PDFInfo
- Publication number
- CN101348789B CN101348789B CN200810130044.0A CN200810130044A CN101348789B CN 101348789 B CN101348789 B CN 101348789B CN 200810130044 A CN200810130044 A CN 200810130044A CN 101348789 B CN101348789 B CN 101348789B
- Authority
- CN
- China
- Prior art keywords
- cell
- nucleic acid
- sequence
- target
- homologous recombination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000006801 homologous recombination Effects 0.000 title claims abstract description 28
- 238000002744 homologous recombination Methods 0.000 title claims abstract description 28
- 102000008300 Mutant Proteins Human genes 0.000 title abstract description 5
- 108010021466 Mutant Proteins Proteins 0.000 title abstract description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 46
- 229920001184 polypeptide Polymers 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 39
- 230000008859 change Effects 0.000 claims abstract description 30
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 108010022394 Threonine synthase Proteins 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 108050006617 Interleukin-1 receptor Chemical group 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Chemical group 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Chemical group 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000012059 conventional drug carrier Substances 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000005034 decoration Methods 0.000 claims 2
- 229940012957 plasmin Drugs 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 abstract description 9
- 108090000144 Human Proteins Proteins 0.000 abstract description 9
- 239000012634 fragment Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010093036 interleukin receptors Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 101150010939 tpa gene Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97112639 | 1997-07-23 | ||
| EP97112639.6 | 1997-07-23 | ||
| CN98807438A CN1265152A (zh) | 1997-07-23 | 1998-07-22 | 通过同源重组在人细胞中生产人突变蛋白 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98807438A Division CN1265152A (zh) | 1997-07-23 | 1998-07-22 | 通过同源重组在人细胞中生产人突变蛋白 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101348789A CN101348789A (zh) | 2009-01-21 |
| CN101348789B true CN101348789B (zh) | 2016-08-17 |
Family
ID=8227102
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810130044.0A Expired - Lifetime CN101348789B (zh) | 1997-07-23 | 1998-07-22 | 通过同源重组在人细胞中生产人突变蛋白 |
| CN98807438A Pending CN1265152A (zh) | 1997-07-23 | 1998-07-22 | 通过同源重组在人细胞中生产人突变蛋白 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98807438A Pending CN1265152A (zh) | 1997-07-23 | 1998-07-22 | 通过同源重组在人细胞中生产人突变蛋白 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6444441B1 (enExample) |
| EP (1) | EP1000167B2 (enExample) |
| JP (1) | JP2001511341A (enExample) |
| KR (1) | KR100512018B1 (enExample) |
| CN (2) | CN101348789B (enExample) |
| AR (2) | AR013251A1 (enExample) |
| AT (1) | ATE313643T1 (enExample) |
| AU (1) | AU729489B2 (enExample) |
| BR (1) | BR9811531A (enExample) |
| CA (1) | CA2297660C (enExample) |
| DE (1) | DE59813296D1 (enExample) |
| DK (1) | DK1000167T4 (enExample) |
| ES (1) | ES2255177T5 (enExample) |
| PT (1) | PT1000167E (enExample) |
| TR (1) | TR200000172T2 (enExample) |
| WO (1) | WO1999005264A2 (enExample) |
| ZA (1) | ZA986517B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102789754B1 (ko) * | 2016-01-06 | 2025-03-31 | 론자 리미티드 | 개선된 생산을 위한 단백질 분해의 억제 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119545A (zh) * | 1993-12-02 | 1996-04-03 | 转移染色体治疗公司 | 蛋白质的生产和蛋白质的输送 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234686A (en) * | 1985-04-03 | 1993-08-10 | Beecham Group P.L.C. | Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| DE3907679A1 (de) * | 1989-03-09 | 1990-09-13 | Max Planck Gesellschaft | Verfahren zur gezielten veraenderung eines gens |
| JPH0576361A (ja) * | 1990-05-10 | 1993-03-30 | Takeda Chem Ind Ltd | 組織プラスミノーゲンアクチベータームテイン |
| US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
| WO1992020808A1 (en) * | 1991-05-15 | 1992-11-26 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| DE69333955D1 (de) * | 1992-04-24 | 2006-02-02 | Stanford Res Inst Int | Targeting homologer sequenzen in eukaryotenzellen |
| WO1994004032A1 (en) * | 1992-08-21 | 1994-03-03 | The Regents Of The University Of California | Composition and method for altering dna sequences by homologous recombination |
| TW402639B (en) * | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| AU6328696A (en) * | 1995-06-07 | 1996-12-30 | Yale University | Treatment of hemoglobinopathies |
| US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
-
1998
- 1998-07-22 WO PCT/EP1998/004583 patent/WO1999005264A2/de not_active Ceased
- 1998-07-22 ES ES98942591T patent/ES2255177T5/es not_active Expired - Lifetime
- 1998-07-22 AT AT98942591T patent/ATE313643T1/de active
- 1998-07-22 PT PT98942591T patent/PT1000167E/pt unknown
- 1998-07-22 DK DK98942591.3T patent/DK1000167T4/da active
- 1998-07-22 JP JP2000504239A patent/JP2001511341A/ja active Pending
- 1998-07-22 BR BR9811531-6A patent/BR9811531A/pt not_active Application Discontinuation
- 1998-07-22 KR KR10-2000-7000697A patent/KR100512018B1/ko not_active Expired - Lifetime
- 1998-07-22 CA CA2297660A patent/CA2297660C/en not_active Expired - Lifetime
- 1998-07-22 US US09/463,338 patent/US6444441B1/en not_active Expired - Lifetime
- 1998-07-22 CN CN200810130044.0A patent/CN101348789B/zh not_active Expired - Lifetime
- 1998-07-22 TR TR2000/00172T patent/TR200000172T2/xx unknown
- 1998-07-22 EP EP98942591A patent/EP1000167B2/de not_active Expired - Lifetime
- 1998-07-22 CN CN98807438A patent/CN1265152A/zh active Pending
- 1998-07-22 DE DE59813296T patent/DE59813296D1/de not_active Expired - Lifetime
- 1998-07-22 ZA ZA9806517A patent/ZA986517B/xx unknown
- 1998-07-22 AU AU90673/98A patent/AU729489B2/en not_active Expired
- 1998-07-23 AR ARP980103617A patent/AR013251A1/es active IP Right Grant
-
2002
- 2002-07-15 US US10/194,244 patent/US20020177195A1/en not_active Abandoned
-
2008
- 2008-08-20 AR ARP080103620A patent/AR068104A2/es not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119545A (zh) * | 1993-12-02 | 1996-04-03 | 转移染色体治疗公司 | 蛋白质的生产和蛋白质的输送 |
Non-Patent Citations (2)
| Title |
|---|
| 邵永源等.基因重组人红细胞生成素的临床应用现状.临床荟萃.1996,11(13),583-584. * |
| 马红京等.基因重组人红细胞生成素治疗癌症病人贫血的临床应用.癌症.1996,15(4),313-314. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU9067398A (en) | 1999-02-16 |
| AR013251A1 (es) | 2000-12-13 |
| US20020068318A1 (en) | 2002-06-06 |
| ATE313643T1 (de) | 2006-01-15 |
| EP1000167B1 (de) | 2005-12-21 |
| BR9811531A (pt) | 2000-08-22 |
| DK1000167T3 (da) | 2006-04-24 |
| PT1000167E (pt) | 2006-05-31 |
| DE59813296D1 (de) | 2006-01-26 |
| ES2255177T3 (es) | 2006-06-16 |
| US6444441B1 (en) | 2002-09-03 |
| CN1265152A (zh) | 2000-08-30 |
| EP1000167A2 (de) | 2000-05-17 |
| EP1000167B2 (de) | 2011-04-20 |
| WO1999005264A2 (de) | 1999-02-04 |
| CN101348789A (zh) | 2009-01-21 |
| TR200000172T2 (tr) | 2000-12-21 |
| KR100512018B1 (ko) | 2005-09-02 |
| CA2297660C (en) | 2010-04-27 |
| ES2255177T5 (es) | 2011-07-12 |
| KR20010022127A (ko) | 2001-03-15 |
| US20020177195A1 (en) | 2002-11-28 |
| ZA986517B (en) | 2000-01-24 |
| AR068104A2 (es) | 2009-11-04 |
| AU729489B2 (en) | 2001-02-01 |
| CA2297660A1 (en) | 1999-02-04 |
| JP2001511341A (ja) | 2001-08-14 |
| WO1999005264A3 (de) | 1999-04-22 |
| DK1000167T4 (da) | 2011-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU629176B2 (en) | Recombinant fibroblast growth factors | |
| AU645539B2 (en) | A recombinant human factor VIII derivative | |
| JPH0655136B2 (ja) | ヒトエリスロポエチンをコードするｄｎａにより形質転換されている細胞 | |
| JPH06500991A (ja) | 骨および軟骨誘導蛋白質 | |
| JP3121611B2 (ja) | 神経成長因子を真核生物細胞において発現させるための遺伝子ベクター | |
| JPH06505631A (ja) | 巨核球刺激因子 | |
| EP0629700A2 (en) | Vector and mammalian cell line having improved productivity | |
| KR20170132784A (ko) | 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터 | |
| CN101348789B (zh) | 通过同源重组在人细胞中生产人突变蛋白 | |
| IE65500B1 (en) | Method of producing peptides recombinant plasmid for use in the same and animal cells transformed with the same | |
| KR20010086587A (ko) | 유전자 요법에 의한 염증성 세포의 자기-조절된 고사 | |
| EP0457527A1 (en) | Plasmids, transformed animal cells and process for producing foreign protein | |
| JPH09295945A (ja) | 成熟型骨誘導因子の製造方法 | |
| US7247716B2 (en) | Recombinant sequence, its preparation and use | |
| JPS6344898A (ja) | ヒトアンチトロンビン３（ａｔ３）の製造 | |
| MXPA00000645A (es) | Produccion de proteinas mutadas humanas en celulas humanas por medio de recombinacion homologa | |
| GB2210620A (en) | Transforming growth factor beta -2 | |
| JPS63141588A (ja) | 組換え体ｄｎａおよび形質転換体 | |
| JPH06279497A (ja) | トロンビン結合性物質及びその製造法 | |
| EP2912173A1 (en) | Process for preparation and purification of recombinant human oncostatin m protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20160817 |
|
| CX01 | Expiry of patent term |